Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Spicer

Showing results (1-10 of 133) with videos related to

Pageof 14
Sort By:
Current Opinion in Molecular Therapeutics|April 23, 2005
Technology evaluation: nimotuzumab, the Center of Molecular Immunology/YM BioSciences/OncoscienceJames Spicer
Current Opinion in Molecular Therapeutics|July 22, 2004
Technology evaluation: pertuzumab, Roche/Genentech/ChugaiJames Spicer
Expert Opinion on Investigational Drugs|February 27, 2009
Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancerDeborah Mukherji, James Spicer
Handbook of Experimental Pharmacology|December 4, 2019
The Evolving Landscape of Cancer TherapeuticsMadeha Khan, James Spicer
Current Biology : CB|June 10, 2004
LKB1 kinase: master and commander of metabolism and polarityJames Spicer, Alan Ashworth
Journal of Thoracic Disease|December 4, 2012
EGFR inhibition and more: a new generation growing upDeborah Enting, James Spicer
The Lancet. Oncology|November 3, 2015
Nedaplatin: a new platinum for squamous lung cancer?Yin Wu, James Spicer
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|November 26, 2008
Targeted therapies in non-small cell lung cancerFiona Kyle, James Spicer
Drug Discovery Today|September 16, 2023
Review of the impact of the FDA's Fast Track Designation on biotechnology companies' share pricesJoab Williamson, Alexander James Spicer
Drug Discovery Today|October 28, 2023
Evaluating the impact of the FDA's orphan drug designation on share prices of biotechnology companiesJoab Williamson, Alexander James Spicer
Pageof 14

Showing results (1-10 of 133) with videos related to

Sort By:
Pageof 14
Current Opinion in Molecular Therapeutics|April 23, 2005
Technology evaluation: nimotuzumab, the Center of Molecular Immunology/YM BioSciences/OncoscienceJames Spicer
Current Opinion in Molecular Therapeutics|July 22, 2004
Technology evaluation: pertuzumab, Roche/Genentech/ChugaiJames Spicer
Expert Opinion on Investigational Drugs|February 27, 2009
Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancerDeborah Mukherji, James Spicer
Handbook of Experimental Pharmacology|December 4, 2019
The Evolving Landscape of Cancer TherapeuticsMadeha Khan, James Spicer
Current Biology : CB|June 10, 2004
LKB1 kinase: master and commander of metabolism and polarityJames Spicer, Alan Ashworth
Journal of Thoracic Disease|December 4, 2012
EGFR inhibition and more: a new generation growing upDeborah Enting, James Spicer
The Lancet. Oncology|November 3, 2015
Nedaplatin: a new platinum for squamous lung cancer?Yin Wu, James Spicer
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|November 26, 2008
Targeted therapies in non-small cell lung cancerFiona Kyle, James Spicer
Drug Discovery Today|September 16, 2023
Review of the impact of the FDA's Fast Track Designation on biotechnology companies' share pricesJoab Williamson, Alexander James Spicer
Drug Discovery Today|October 28, 2023
Evaluating the impact of the FDA's orphan drug designation on share prices of biotechnology companiesJoab Williamson, Alexander James Spicer
Pageof 14